On Mar. 7, 1977, the U.S. Food and Drug Administration approved Bristol-Myers’ BICNU (carmustine), for the treatment of brain and lymphatic cancers.

BiCNU is a nitrosourea indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents.